Mr. Ken d'Entremont reports

MEDEXUS SCHEDULES SECOND FISCAL QUARTER 2026 CONFERENCE CALL

Medexus Pharmaceuticals Inc. plans to host a conference call at 8 a.m. Eastern Time on Thursday, Nov. 13, 2025, to discuss Medexus's results for its second fiscal quarter ended Sept. 30, 2025. Medexus expects to file its financial statements and MD&A (management's discussion and analysis) after markets close on Nov. 12, 2025.

To participate in the call, please dial the following numbers:

• 877-545-0523 (toll-free) for Canadian and U.S. callers;
• 1-973-528-0016 for international callers;
• Access code 988000.

A live webcast of the call will be available on the investors section of Medexus's corporate website.

A replay of the call will be available approximately one hour following the end of the call through Thursday, Nov. 20, 2025. To access the replay, please dial the following numbers:

• 1-877-481-4010 for Canadian and U.S. callers;
• 1-919-882-2331 for international callers;
• Conference ID No. 53180.

A replay of the webcast will be available on the investors section of Medexus's corporate website until Friday, Nov. 13, 2026.

About Medexus Pharmaceuticals Inc.

Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of hematology and hematology-oncology and rheumatology, allergy, and dermatology. For more information about Medexus and its product portfolio, please see the company's corporate website and its filings on SEDAR+.

We seek Safe Harbor.